2024
Akinloye, A., Oyedeji, T., Eniayewu, O., Adeagbo, B., Bolaji, O., Rannard, S., . . . Olagunju, A. (n.d.). Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers. Future Pharmacology, 4(1), 163-172. doi:10.3390/futurepharmacol4010011DOI: 10.3390/futurepharmacol4010011
Atoyebi, S., Bunglawala, F., Cottura, N., Grañana-Castillo, S., Montanha, M., Olagunju, A., . . . Waitt, C. (2024). Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. British Journal of Clinical Pharmacology. doi:10.1111/bcp.16006DOI: 10.1111/bcp.16006
2023
Buzibye, A., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study.. AIDS research and therapy, 20(1), 20. doi:10.1186/s12981-023-00514-2DOI: 10.1186/s12981-023-00514-2
2022
Neary, M., Owen, A., & Olagunju, A. (2022). A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm. Clinical Infectious Diseases, 75(Supplement_4), S490-S497. doi:10.1093/cid/ciac685DOI: 10.1093/cid/ciac685
Olagunju, A., Mathad, J., Eke, A., Delaney-Moretlwe, S., & Lockman, S. (2022). Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation. Clinical Infectious Diseases, 75(Supplement_4), S571-S578. doi:10.1093/cid/ciac659DOI: 10.1093/cid/ciac659
Fowotade, A., Bamidele, F., Egbetola, B., Fagbamigbe, A. F., Adeagbo, B. A., Adefuye, B. O., . . . Olagunju, A. (2022). A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. FRONTIERS IN MEDICINE, 9. doi:10.3389/fmed.2022.956123DOI: 10.3389/fmed.2022.956123
Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S. H., . . . Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00462-3DOI: 10.1186/s12981-022-00462-3
Akinloye, A., Eniayewu, O., Adeagbo, B., Bolaji, O., & Olagunju, A. (2022). Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots. THERAPEUTIC DRUG MONITORING, 44(3), 430-437. doi:10.1097/FTD.0000000000000929DOI: 10.1097/FTD.0000000000000929
Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 (Preprint)
DOI: 10.1101/2022.02.03.22270152
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2DOI: 10.12688/wellcomeopenres.17202.2
2021
Shenkoya, B., Atoyebi, S., Eniayewu, I., Akinloye, A., & Olagunju, A. (2021). Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester. FRONTIERS IN PEDIATRICS, 9. doi:10.3389/fped.2021.734122DOI: 10.3389/fped.2021.734122
Eke, A. C., Olagunju, A., Momper, J., Penazzato, M., Abrams, E. J., Best, B. M., . . . Colbers, A. (2021). Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. CLINICAL PHARMACOLOGY & THERAPEUTICS, 110(1), 36-48. doi:10.1002/cpt.2048DOI: 10.1002/cpt.2048
Nwogu, J. N., Gandhi, M., Owen, A., Khoo, S., Taiwo, B., Olagunju, A., . . . Babalola, C. P. (2021). Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.. AIDS (London, England). doi:10.1097/qad.0000000000002984DOI: 10.1097/qad.0000000000002984
Olagunju, A., Fowotade, A., Olagunoye, A., Ojo, T. O., Adefuye, B. O., Fagbamigbe, A. F., . . . Owen, A. (2021). Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 22(1). doi:10.1186/s13063-020-04987-8DOI: 10.1186/s13063-020-04987-8
2020
Eke, A. C., Olagunju, A., Best, B. M., Mirochnick, M., Momper, J. D., Abrams, E., . . . Colbers, A. (n.d.). Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. Clinical Pharmacokinetics. doi:10.1007/s40262-020-00915-wDOI: 10.1007/s40262-020-00915-w
Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients (Journal article)
Dragovic, G., Dimitrijevic, B., Kusic, J., Soldatovic, I., Jevtovic, D., Olagunju, A., & Owen, A. (2020). Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 86(7), 1289-1295. doi:10.1111/bcp.14230DOI: 10.1111/bcp.14230
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz (Journal article)
Adegbola, A. J., Rana, A., Adeagbo, B. A., Bolarinwa, R. A., Olagunju, A. E., Siccardi, M., . . . Bolaji, O. O. (2020). Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. PHARMACOGENETICS AND GENOMICS, 30(5), 96-106. doi:10.1097/FPC.0000000000000401DOI: 10.1097/FPC.0000000000000401
Pharmacokinetics of HIV therapies in pregnant patients: an update (Journal article)
Neary, M., Owen, A., & Olagunju, A. (2020). Pharmacokinetics of HIV therapies in pregnant patients: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 16(6), 449-461. doi:10.1080/17425255.2020.1754792DOI: 10.1080/17425255.2020.1754792
Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population (Journal article)
Neary, M., Olagunju, A., Sarfo, F., Phillips, R., Moss, D., Owen, A., & Chadwick, D. (2020). Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1267-1271. doi:10.1093/jac/dkaa008DOI: 10.1093/jac/dkaa008
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). <i>CYP2B6</i>*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. JOURNAL OF CLINICAL PHARMACOLOGY, 60(3), 351-360. doi:10.1002/jcph.1527DOI: 10.1002/jcph.1527
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(3). doi:10.1128/AAC.00947-19DOI: 10.1128/AAC.00947-19
Development and clinical validation of an liquid chromatography with ultraviolet detection method to quantify dolutegravir in dried blood spots (Conference Paper)
Akinloye, A., Adeagbo, B., Bolaji, O., & Olagunju, A. (2020). Development and clinical validation of an liquid chromatography with ultraviolet detection method to quantify dolutegravir in dried blood spots. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 23 (pp. 90). Retrieved from https://www.webofscience.com/
2019
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies (Journal article)
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068DOI: 10.1016/j.ejps.2019.105068
Francis, J., Zvada, S. P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., . . . McIlleron, H. M. (2019). A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(4). doi:10.1128/AAC.01964-18DOI: 10.1128/AAC.01964-18
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111DOI: 10.2217/pgs-2018-0111
Abdullahi, S. T., Olagunju, A., Soyinka, J. O., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2019). Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. British journal of clinical pharmacology. doi:10.1111/bcp.13821DOI: 10.1111/bcp.13821
Olagunju, A., Anweh, D., Okafor, O., Dickinson, L., Richman, D., Owen, A., & Adejuyigbe, E. (2019). Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. doi:10.12688/wellcomeopenres.15072.1DOI: 10.12688/wellcomeopenres.15072.1
2018
Adegbola, A., Abutaima, R., Olagunju, A., Ijarotimi, O., Siccardi, M., Owen, A., . . . Bolaji, O. (2018). Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(10). doi:10.1128/AAC.01252-18DOI: 10.1128/AAC.01252-18
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1DOI: 10.12688/aasopenres.12860.1
Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs. Journal of Antimicrobial Chemotherapy, 73(4), 1013-1019. doi:10.1093/jac/dkx507DOI: 10.1093/jac/dkx507
Olagunju, A., Schipani, A., Bolaji, O., Khoo, S., & Owen, A. (2018). Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(1), 165-172. doi:10.1093/jac/dkx334DOI: 10.1093/jac/dkx334
2017
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667DOI: 10.1002/cpt.667
Waitt, C., Penchala, S. D., Olagunju, A., Amara, A., Else, L., Lamorde, M., & Khoo, S. (2017). Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. Journal of Chromatography B, 1060, 300-307. doi:10.1016/j.jchromb.2017.06.012DOI: 10.1016/j.jchromb.2017.06.012
Quality of artemisinin-based antimalarial drugs marketed in Nigeria (Journal article)
Izevbekhai, O., Adeagbo, B., Olagunju, A., & Bolaji, O. (2017). Quality of artemisinin-based antimalarial drugs marketed in Nigeria. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 111(2), 90-96. doi:10.1093/trstmh/trx019DOI: 10.1093/trstmh/trx019
2016
Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study (Journal article)
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227DOI: 10.1097/FPC.0000000000000227
Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis (Journal article)
Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016DOI: 10.2217/pgs-2015-0016
Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy. (Conference Paper)
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.
Bienczak, A., Cook, A., Wiesner, L., Olagunju, A., Mulenga, V., Kityo, C., . . . Denti, P. (2016). The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 82(1), 185-198. doi:10.1111/bcp.12934DOI: 10.1111/bcp.12934
2015
Class-specific relative genetic contribution for key antiretroviral drugs (Journal article)
Siccardi, M., Olagunju, A., Simiele, M., D'Avolio, A., Calcagno, A., Di Perri, G., . . . Owen, A. (2015). Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 70(11), 3074-3079. doi:10.1093/jac/dkv207DOI: 10.1093/jac/dkv207
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots (Journal article)
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174DOI: 10.1093/jac/dkv174
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317DOI: 10.1093/cid/civ317
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127DOI: 10.1097/FTD.0000000000000127
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43DOI: 10.1002/cpt.43
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420DOI: 10.1093/jac/dku420
2014
<i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients (Journal article)
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). <i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098DOI: 10.1097/FTD.0000000000000098
<i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults (Journal article)
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073DOI: 10.1097/FPC.0000000000000073
2013
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Journal article)
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67DOI: 10.2217/fvl.13.67
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Siccardi, M., Olagunju, A., Seden, K., Ebrahimjee, F., Rannard, S., Back, D., & Owen, A. (2013). Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.. In silico pharmacology, 1, 4. doi:10.1186/2193-9616-1-4DOI: 10.1186/2193-9616-1-4
2012
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding (Journal article)
Olagunju, A., Owen, A., & Creesey, T. R. (2012). Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. PHARMACOGENOMICS, 13(13), 1501-1522. doi:10.2217/PGS.12.138DOI: 10.2217/PGS.12.138
